Reduction in Staphylococcus aureus bacteraemia rates in patients receiving haemodialysis following alteration of skin antisepsis procedures

Summary This study examined all cases of Staphylococcus aureus bacteraemia (SAB) in the haemodialysis cohort at the Royal Darwin Hospital, Australia over a seven-year period. Midway through this period, antisepsis for arteriovenous fistulae (AVF) and central venous catheters (CVC) changed from 0.5%...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of hospital infection Vol. 92; no. 2; pp. 191 - 193
Main Authors Stewart, B.J, Gardiner, T, Perry, G.J, Tong, S.Y.C
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.02.2016
Subjects
Anti-Infective Agents, Local - administration & dosage
Antisepsis - methods
ANZDATA
Arteriovenous fistula
Australia - epidemiology
Bacteremia - epidemiology
Bacteremia - microbiology
Bacteremia - prevention & control
Catheter-Related Infections - epidemiology
Catheter-Related Infections - microbiology
Catheter-Related Infections - prevention & control
Central venous catheter
Chlorhexidine
Chlorhexidine - administration & dosage
Haemodialysis
Hospitals
Humans
Infectious Disease
Renal Dialysis - adverse effects
Retrospective Studies
Skin - microbiology
Staphylococcal Infections - epidemiology
Staphylococcal Infections - microbiology
Staphylococcal Infections - prevention & control
Staphylococcus aureus
Staphylococcus aureus - isolation & purification
Australia
Central venous catheter
Arteriovenous fistula
Chlorhexidine
Haemodialysis
ANZDATA
Staphylococcus aureus
Online AccessGet full text

Cover

More Information
Summary:Summary This study examined all cases of Staphylococcus aureus bacteraemia (SAB) in the haemodialysis cohort at the Royal Darwin Hospital, Australia over a seven-year period. Midway through this period, antisepsis for arteriovenous fistulae (AVF) and central venous catheters (CVC) changed from 0.5% chlorhexidine solution to 2% chlorhexidine solution. Rates of SAB episodes were calculated using registry data. Trends in SAB over time were analysed using an interrupted regression analysis. Following the change to 2% chlorhexidine, average SAB rates decreased by 68%, and it is estimated that 0.111 cases of SAB/patient-year were prevented. CVC-related SAB rates remained low throughout. These results support the use of 2% chlorhexidine in skin antisepsis for patients with AVF.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0195-6701
1532-2939
DOI:10.1016/j.jhin.2015.10.022